AbbVie Inc. ABBV
NYSE · Healthcare · Drug Manufacturers - General
$286.20
Close on Fri, 20 Nov 2026 · market value $506B
What the price is betting on
Below its recordAt $286, the price assumes revenue grows about 3.2% a year for five years, from $66B to about $75.4B by FY2030. That is less than what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 6.6% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than ABBV? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$315
Base
$379
Bull
$456
Today $286
- Bear $315. Cash flow grows 5% a year for the next 5 years, slower than expected, then slows to long-run growth.
- Base $379. Cash flow grows 8% a year for the next 5 years, as analysts expect, then slows to long-run growth.
- Bull $456. Cash flow grows 11% a year for the next 5 years, faster than expected, then slows to long-run growth.
Stories set by rules from the company’s record.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$66.5B$67.7B, on the path
- FY2027$68.6B$73.8B, on the path
- FY2028$70.8B$79.7B, on the path
- FY2029$73B$84.2B, on the path
- FY2030$75.4B$86.4B, on the path
Each year's revenue at 3.2% growth from $66B in the 12 months to September 2026.
At a glance
Healthcare · Drug Manufacturers - General · listed on NYSE
- Revenue, FY2025
- $61.2B
- Growth, 3 years a year
- 7.4%
- Cash margin
- 29%
- Net debt
- $63.8B
- Shares, 3-year change
- −0.2%
- Dividend yield
- 2.3%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.